Outlook Therapeutics heads into its fiscal Q2 earnings release tomorrow — May 14 — with short sellers having tripled their position in six weeks and the options market tilting heavily toward calls.
Short interest has surged from roughly 2.6% of free float in early April to 8.3% today. That is a more than 200% gain in six weeks. The most recent weekly move alone added 27% to the short position, though Tuesday saw a partial unwind of about 10%. The raw short score of 63.5 reflects the elevated pressure, even as days-to-cover remain short at 1.2 days per the latest FINRA data — suggesting this is a conviction bet rather than a slow-building structural position. Borrow availability has tightened alongside the build: the lending pool is now more than half consumed, with availability having pulled in sharply from the loose conditions seen before mid-April.
Cost to borrow has drifted lower even as the short position grew, easing from above 12% in early April to 8.5% today. That apparent contradiction tells a meaningful story: supply of lendable shares kept pace with demand through May, so shorts were able to build without paying up for the privilege. The 52-week peak on borrow availability sat near 97% utilisation — the current 44% reading means the pool is tighter than it was in March but not yet approaching a stress point.
Options positioning reinforces the bullish tilt. The put/call ratio is running at just 0.08, well below its 20-day average of 0.10 and near the lowest level of the past year. That low PCR indicates options activity is dominated by calls — consistent with speculative positioning around a binary event. The z-score of -1.1 confirms calls are running unusually heavy relative to recent norms.
The Street's view has deteriorated steadily. The most recent analyst action on record — from Ascendiant Capital in March — cut its price target from $10 to $6 while holding a Buy. Two other active names, HC Wainwright and Chardan, both rate the stock Neutral with targets of $0.50 and $1.00 respectively, well below even the current $0.24 price on the $6 target outlier. The bear case centres on a stalled FDA path for its bevacizumab eye-drop candidate ONS-5010, a thin cash runway, and ongoing dilution risk. The bull case rests on European commercial traction for LYTENAVA in the UK and Germany, but progress there has been slow. Given the current stock price of $0.2425, the analyst data carries significant uncertainty around currency and share-count assumptions — note the mean target of $4.17 looks stale and may not reflect the company's capital structure following subsequent share issuances.
Earnings history adds further caution. All four of the most recent releases produced negative next-day reactions, ranging from -2% to -16%, with follow-through selling over the subsequent five days in three of those four cases. The most severe — a February 2026 event — saw the stock fall 16% on the day and another 16% over the following week. With short interest at a multi-month high and options traders leaning aggressively to the call side, tomorrow's print is shaping up as a genuine two-way catalyst: whether management can offer any clarity on the European revenue ramp or a clearer financing path will define how quickly either the call buyers or the short sellers are proven right.
See the live data behind this article on ORTEX.
Open OTLK on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
